These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2029 related articles for article (PubMed ID: 34416901)

  • 1. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
    Hong W; Xue M; Jiang J; Zhang Y; Gao X
    J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 5. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
    You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
    Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer.
    Luo YH; Yang YP; Chien CS; Yarmishyn AA; Adekunle Ishola A; Chien Y; Chen YM; Tsai PH; Lin TW; Wang ML; Chiou SH
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circular RNA hsa_circ_0068252 Functions in Cisplatin Resistance and Immune Response via miR-1304-5p/PD-L1 Axis in Non-Small Cell Lung Cancer.
    Li J; Xu J; Wu G; Ren Y; Wang X; Zhang Q
    Chemotherapy; 2022; 67(4):223-233. PubMed ID: 35649347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis.
    Zhang N; Fan J; Deng Z
    Anticancer Drugs; 2022 Jun; 33(5):437-447. PubMed ID: 35324518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circular RNA circ_0101675 Promotes NSCLC Cell Proliferation, Migration, Invasion, Angiogenesis and Immune Evasion by Sponging miR-607/PDL1 Axis.
    Lu W; Li L; Li L; Guo N; Ma X
    Biochem Genet; 2024 Jun; 62(3):1539-1555. PubMed ID: 37646893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC Axis and PD-L1 phosphorylation.
    Miao Z; Li J; Wang Y; Shi M; Gu X; Zhang X; Wei F; Tang X; Zheng L; Xing Y
    Mol Cancer; 2023 Dec; 22(1):205. PubMed ID: 38093288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
    Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
    J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. circATAD2 mitigates CD8
    Zhang Z; Huo W; Li J
    Cancer Immunol Immunother; 2024 May; 73(7):130. PubMed ID: 38748254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
    Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
    Chem Biol Interact; 2021 Nov; 349():109652. PubMed ID: 34520751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin α2 promotes immune escape in non-small-cell lung cancer by enhancing PD-L1 expression in exosomes to inhibit CD8 + T-cell activity.
    Jing H; Meng M; Ye M; Liu S; Cao X; Li K; Liu Y; Zhang J; Wu Y
    J Investig Med; 2024 Jan; 72(1):57-66. PubMed ID: 37804164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer cell-derived exosomal circUSP7 induces CD8
    Chen SW; Zhu SQ; Pei X; Qiu BQ; Xiong D; Long X; Lin K; Lu F; Xu JJ; Wu YB
    Mol Cancer; 2021 Nov; 20(1):144. PubMed ID: 34753486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.
    Huang Y; Xia L; Tan X; Zhang J; Zeng W; Tan B; Yu X; Fang W; Yang Z
    Cell Mol Biol Lett; 2022 Jun; 27(1):43. PubMed ID: 35658874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1/PD-L1 checkpoint.
    Lei J; Zhu J; Hui B; Jia C; Yan X; Jiang T; Wang X
    Cancer Immunol Immunother; 2023 Jan; 72(1):101-124. PubMed ID: 35750765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 102.